Search

Alkermes PLC

Geschlossen

BrancheGesundheitswesen

41.42 -0.12

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

41.15

Max

42.67

Schlüsselkennzahlen

By Trading Economics

Einkommen

67M

501K

Verkäufe

103M

496M

KGV

Branchendurchschnitt

112.526

47.946

EPS

0.52

Gewinnspanne

0.101

Angestellte

2,050

EBITDA

76M

54M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+41.86% upside

Dividenden

By Acuity

Nächstes Ergebnis

27. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.6B

7.2B

Vorheriger Eröffnungskurs

41.54

Vorheriger Schlusskurs

41.42

Nachrichtenstimmung

By Acuity

50%

50%

115 / 340 Ranking in Healthcare

Alkermes PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Okt. 2026, 19:51 UTC

Alkermes Plc shares fell sharply, continuing a notable decline since Monday's close amid broader market conditions and trading below its 20-day moving average.

5. Okt. 2026, 23:40 UTC

Alkermes Plc is trading higher in after-market hours, extending its upward trend after three consecutive sessions of gains amid positive biotechnology sector performance.

2. Okt. 2026, 19:26 UTC

Alkermes Plc is trading sharply higher, recovering from earlier lows, despite remaining below its 20-day moving average and near the lower end of its one-month range.

1. Okt. 2026, 22:50 UTC

Alkermes Plc declined in after-market trading, moving lower since Thursday's close and positioning the stock below its 20-day moving average.

29. Sept. 2026, 20:07 UTC

Alkermes Plc closed higher in Tuesday's trading session, despite notable volatility, finishing above Monday's close but below its 20-day moving average.

28. Sept. 2026, 19:16 UTC

News

Alkermes Plc shares fell modestly, continuing a decline since Friday and trading near the lower end of their one-month range.

24. Sept. 2026, 20:01 UTC

News

Alkermes Plc shares fell sharply as Goldman Sachs resumed coverage with a Neutral rating and a $50.00 price target, contributing to the stock's decline.

23. Sept. 2026, 20:07 UTC

Alkermes Plc shares fell sharply today, hitting a midday low and remaining below the 20-day moving average after earlier strength in the session.

22. Sept. 2026, 20:01 UTC

Event

Alkermes Plc reported positive results from a phase 1 study for ALKS 7290, yet shares fell sharply, remaining below their 20-day moving average.

21. Sept. 2026, 23:51 UTC

Event

Alkermes Plc's stock is declining in after-market trading despite positive phase 1 results for ALKS 7290, remaining below its 20-day moving average.

18. Sept. 2026, 20:02 UTC

Alkermes Plc shares fell sharply, reversing recent upward momentum, with a decline following a series of higher daily closes since Thursday's close.

17. Sept. 2026, 19:36 UTC

Alkermes Plc is trading higher, having previously peaked, but remains below its 20-day moving average and near the lower end of its one-month range.

15. Sept. 2026, 19:56 UTC

Alkermes Plc is trading higher today, with no specific news identified. Investor sentiment is influenced by expectations of a Federal Reserve rate hike.

14. Sept. 2026, 19:16 UTC

Alkermes Plc shares are lower amid negative market sentiment over inflation and supply chain issues, nearing the lower end of their one-month range.

11. Sept. 2026, 19:36 UTC

Alkermes shares are lower in Friday's session, lacking specific news. The broader market reacts to the Consumer Price Index release amid interest rate speculation.

10. Sept. 2026, 20:13 UTC

Alkermes Plc shares are lower in after-market trading, reflecting bearish sentiment amid the European Central Bank's interest rate hike and inflation concerns.

9. Sept. 2026, 20:07 UTC

Alkermes Plc shares are lower today, continuing a recent downward trend amid no specific news. The stock remains below its 20-day moving average.

8. Sept. 2026, 21:31 UTC

Alkermes Plc rose in after-market trading, gaining momentum despite broader market pressures and rising crude oil prices. No specific news was identified to explain the move.

4. Sept. 2026, 19:36 UTC

Alkermes Plc shares are lower amid broader market pressure from rising Treasury yields and expectations of tighter monetary policy from the Federal Reserve.

3. Sept. 2026, 22:01 UTC

Alkermes Plc shares are trading higher in after-market hours, amid a decline in ten-year Treasury yields that may be boosting overall market sentiment.

2. Sept. 2026, 21:01 UTC

Alkermes Plc's shares are lower in after-market hours, continuing a downward trend since Wednesday. The stock is near the lower end of its one-month range.

31. Aug. 2026, 20:07 UTC

Alkermes shares are lower during Monday's session amid ongoing inflation concerns and expectations for a Federal Reserve interest rate hike.

28. Aug. 2026, 22:36 UTC

Alkermes Plc shares are higher in after-market trading, following a notable increase earlier in the session. No specific news was identified to explain the move.

27. Aug. 2026, 19:51 UTC

Alkermes Plc shares are lower amid significant downward pressure on biotechnology stocks. Earlier in the session, shares pulled back from a session high.

26. Aug. 2026, 19:16 UTC

Alkermes Plc shares are lower today, reaching a session low earlier. No specific news was identified to explain the decline.

21. Aug. 2026, 19:51 UTC

Alkermes Plc's shares are higher, supported by strong biotechnology sector momentum, though the stock is pulling back from earlier session highs.

20. Aug. 2026, 20:01 UTC

Alkermes Plc shares are lower, impacted by broader weakness in the Biotechnology sector. The stock is trading below its 20-day moving average.

19. Aug. 2026, 19:26 UTC

Alkermes Plc is trading higher, maintaining momentum since Tuesday's close, despite no specific news driving the price movement.

18. Aug. 2026, 19:16 UTC

News

Alkermes Plc shares are lower after an insider sold 7,576 shares at prices between $49.19 and $49.65, raising investor concerns about the outlook.

17. Aug. 2026, 23:31 UTC

Alkermes Plc shares are higher in after-market trading, reflecting a cumulative gain since Monday's close amid broader market volatility and fluctuating crude oil prices.

Peer-Vergleich

Kursveränderung

Alkermes PLC Prognose

Kursziel

By TipRanks

41.86% Vorteil

12-Monats-Prognose

Durchschnitt 59.083 USD  41.86%

Hoch 83 USD

Tief 38 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alkermes PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

9

Buy

3

Halten

1

Sell

Stimmung

By Acuity

115 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.